Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT1 | Q03111 | 20/20 | 0.68 |
| ▸ | MLLT3 | P42568 | 2/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.68 |
| ▸ | PIM1 | P11309 | 1/20 | 0.68 |
| ▸ | ACHE | P22303 | 1/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.68 |
| ▸ | TRIB2 | Q92519 | 1/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30293626 | 1.00 | MLLT1 (0.68) | MLLT1MLLT3CHRM2PIM1ACHE | |
| SCHEMBL30293563 | 0.90 | MLLT1 (0.65) | MLLT1MLLT3CHRM2PIM1ACHE | |
| SCHEMBL24376311 | 0.90 | MLLT1 (0.65) | MLLT1MLLT3CHRM2PIM1ACHE | |
| SCHEMBL24376312 | 0.87 | MLLT1 (0.88) | MLLT1MLLT3CHRM2PIM1ACHE | |
| SCHEMBL24376332 | 0.87 | MLLT1 (0.62) | MLLT1MLLT3CHRM2PIM1ACHE | |
| SCHEMBL29622143 | 0.87 | MLLT1 (0.62) | MLLT1MLLT3CHRM2PIM1ACHE | |
| SCHEMBL24376319 | 0.86 | MLLT1 (0.66) | MLLT1MLLT3CHRM2PIM1ACHE | |
| SCHEMBL24376342 | 0.86 | MLLT1 (0.65) | MLLT1MLLT3CHRM2PIM1ACHE | |
| SCHEMBL24376425 | 0.86 | MLLT1 (0.65) | MLLT1MLLT3CHRM2PIM1ACHE | |
| SCHEMBL24376457 | 0.86 | MLLT1 (0.65) | MLLT1MLLT3CHRM2PIM1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023038500-A1 | COMPOUND FOR DEGRADING ENL PROTEIN AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2023-03-16 | — | — | WO | disclosed |